Accessibility navigation


The neurokinin 1 receptor: a potential new target for anti-platelet therapy?

Jones, S. and Gibbins, J. M. (2008) The neurokinin 1 receptor: a potential new target for anti-platelet therapy? Current Opinion in Pharmacology, 8 (2). pp. 114-119. ISSN 1471-4892

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1016/j.coph.2008.01.004

Abstract/Summary

The important role of platelets in the development of arterial thrombosis and cardiovascular disease is well established. Current treatments for arterial thrombosis include anti-platelet agents such as aspirin, thienopyridines and glycoprotein IIb-IIIa inhibitors. Despite these drugs being effective there remains a substantial unmet clinical demand for more effective therapeutic approaches, which may reflect the existence of alternative underlying regulatory mechanisms to those already targeted. Recent publications have demonstrated a key role for tachykinins in the positive feedback regulation of platelet aggregation and thrombus formation. The pro-thrombotic effects of tachykinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel therapeutic drug target in the prevention and the treatment of arterial thrombosis.

Item Type:Article
Refereed:Yes
Divisions:Interdisciplinary centres and themes > Institute for Cardiovascular and Metabolic Research (ICMR)
Faculty of Life Sciences > School of Biological Sciences
ID Code:9826
Uncontrolled Keywords:PERIPHERAL TACHYKININ RECEPTORS, SUBSTANCE-P, THROMBUS FORMATION, PHARMACOLOGICAL PROFILE, MAMMALIAN TACHYKININ, ARACHIDONATE CASCADE, PLATELETS, ASPIRIN, CLOPIDOGREL, ANTAGONISTS
Publisher:Elsevier

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation